Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Takara Bio's Revenue for the
three
months ended in Mar. 2026 was €65.0 Mil. Takara Bio's average Accounts Receivable for the
three
months ended in Mar. 2026 was €49.7 Mil.
Hence, Takara Bio's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.31.
Takara Bio (FRA:TF2) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Takara Bio Receivables Turnover Related Terms
Takara Bio Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Takara Bio's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TF2 vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Takara Bio's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Takara Bio's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takara Bio (FRA:TF2) has a Receivables Turnover of 1.31 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Takara Bio and its competitors. According to the industry distribution chart, Takara Bio ranks #538 out of 841 companies in the Biotechnology industry, placing it in the top 64%.
Is Takara Bio's Receivables Turnover too high?
Takara Bio's current Receivables Turnover is 1.31. The Biotechnology industry median Receivables Turnover is 5.29. Takara Bio's value of 1.31 is 75.2% below this industry median. Based on the distribution chart, Takara Bio ranks #538 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Takara Bio has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #538 out of 841 companies for Receivables Turnover. This places Takara Bio in the lower half of its industry. The industry median Receivables Turnover is 5.29. Takara Bio's value of 1.31 is 75.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Takara Bio's current Receivables Turnover of 1.31 is 75.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Takara Bio and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takara Bio's current Receivables Turnover is 1.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Takara Bio (FRA:TF2) has a current Receivables Turnover of 1.31. The stock's GF Value™ is €4.47, compared to a current price of €5.95 — trading 33.1% above its estimated fair value. The current Receivables Turnover is 1.31 and 75.2% below the Biotechnology industry median of 5.29. Takara Bio's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current Receivables Turnover is 1.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (FRA:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €5.95 is trading 33.1% above its estimated GF Value™ of €4.47.
Key valuation signals for FRA:TF2:
Receivables Turnover: 1.31
GF Value™: €4.47 vs. price of €5.95 (33.1% above fair value)
Industry Position: 75.2% below the Biotechnology median (#538 of 841)
No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
50GF Score
Get the complete analysis for FRA:TF2
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TF2 has been successfully added to your 
